CPT® Molecular Pathology Tier 2 Codes

Most recent changes to the CPT® Molecular Pathology Tier 2 Codes document

• Revision of code 81406 from the February 2017 CPT Editorial Panel meeting

This document contains new or revised codes for Molecular Pathology (MoPath) Tier 2 procedures that have been approved at the most recent CPT Editorial Panel meetings and are provided to facilitate accurate reporting of molecular pathology procedures.

To assist users in reporting the most recently approved MoPath Tier 2 codes, this document will be updated with early publication of these codes in July, January, and March in a given CPT cycle. These dates for early release coincide with completion of Panel actions following each of the three CPT Editorial Panel meetings in a given CPT cycle (May, October, and February). The table below details the publishing timelines for Category I MoPath Tier 2 codes.

<table>
<thead>
<tr>
<th>Panel Meeting Approval</th>
<th>Published to the AMA Website</th>
<th>Effective Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>February</td>
<td>March 1</td>
<td>July 1</td>
</tr>
<tr>
<td>May</td>
<td>July 1</td>
<td>January 1</td>
</tr>
<tr>
<td>October</td>
<td>January 1</td>
<td>July 1</td>
</tr>
</tbody>
</table>

For these codes, as well as other CPT codes, inclusion of a descriptor and its associated code number in the CPT code set does not represent endorsement by the AMA of any particular diagnostic procedure or service. Inclusion or exclusion of a procedure or service does not imply any health insurance coverage or reimbursement policy.

It is important to note that further CPT Editorial Panel or Executive Committee actions may affect these codes and/or descriptors. For this reason, code numbers and/or descriptor language may differ at the time of publication in the CPT codeset. In addition, further Panel actions may result in gaps in code number sequencing.
<table>
<thead>
<tr>
<th>Code</th>
<th>Long Code Descriptor</th>
<th>Published to AMA Website</th>
<th>Effective Date</th>
<th>Publication</th>
</tr>
</thead>
</table>
| ▲81400 | Molecular pathology procedure, Level 1 (eg, identification of single germline variant [eg, SNP] by techniques such as restriction enzyme digestion or melt curve analysis)  
  *DPYD (dihydropyrimidine dehydrogenase) (eg, 5-fluorouracil/5-FU and capecitabine drug metabolism), IVS14+1G>A variant*  
  *Human Platelet Antigen 1 genotyping (HPA-1), ITGB3 (integrin, beta 3 [platelet glycoprotein IIIa, antigen CD61 [GPIIIa]) (eg, neonatal alloimmune thrombocytopenia [NAIT], post-transfusion purpura), HPA-1a/b (L33R)*  
  *Human Platelet Antigen 2 genotyping (HPA-2), GP1BA (glycoprotein Ib [platelet], alpha polypeptide [GPIba]) (eg, neonatal alloimmune thrombocytopenia [NAIT], post-transfusion purpura), HPA-2a/b (T145M)*  
  *Human Platelet Antigen 3 genotyping (HPA-3), ITGA2B (integrin, alpha 2b [platelet glycoprotein IIb of IIb/IIIa complex], antigen CD41 [GPIIb]) (eg, neonatal alloimmune thrombocytopenia [NAIT], post-transfusion purpura), HPA-3a/b (I843S)*  
  *Human Platelet Antigen 4 genotyping (HPA-4), ITGB3 (integrin, beta 3 [platelet glycoprotein IIIa, antigen CD61 [GPIIIa]) (eg, neonatal alloimmune thrombocytopenia [NAIT], post-transfusion purpura), HPA-4a/b (R143Q)*  
  *Human Platelet Antigen 5 genotyping (HPA-5), ITGA2 (integrin, alpha 2 [CD49B, alpha 2 subunit of VLA-2 receptor], [GPIa]) (eg, neonatal alloimmune thrombocytopenia [NAIT], post-transfusion purpura), HPA-5a/b (K505E)*  
  *Human Platelet Antigen 6 genotyping (HPA-6w), ITGB3 (integrin, beta 3 [platelet glycoprotein IIIa, antigen CD61 [GPIIIa]) (eg, neonatal alloimmune thrombocytopenia [NAIT], post-transfusion purpura), HPA-6a/b (R489Q)*  
  *Human Platelet Antigen 9 genotyping (HPA-9w), ITGA2B (integrin, alpha 2b [platelet glycoprotein IIb of IIb/IIIa complex], antigen CD41 [GPIIb]) (eg, neonatal alloimmune thrombocytopenia [NAIT], post-transfusion purpura), HPA-9a/b (V837M)*  
  *Human Platelet Antigen 15 genotyping (HPA-15), CD109 (CD109 molecule) (eg, neonatal alloimmune thrombocytopenia [NAIT], post-transfusion purpura), HPA-15a/b (S682Y)*  
  *IL28B (interleukin 28B [interferon, lambda 3]) (eg, drug response), rs12979860 variant*  
  *SLCO1B1 (solute carrier organic anion transporter family, member 1B1) (eg, adverse drug reaction), V174A variant* | January 1, 2017 | July 1, 2017 | CPT® 2018 |
<table>
<thead>
<tr>
<th>Code</th>
<th>Long Code Descriptor</th>
<th>Published to AMA Website</th>
<th>Effective Date</th>
<th>Publication</th>
</tr>
</thead>
</table>
| ▲81401 | Molecular pathology procedure, Level 2 (eg, 2-10 SNPs, 1 methylated variant, or 1 somatic variant [typically using nonsequencing target variant analysis], or detection of a dynamic mutation disorder/triplet repeat)  
TPMT (thiopurine S-methyltransferase) (eg, drug metabolism), common variants (eg, *2, *3)  
TYMS (thymidylate synthetase) (eg, 5-fluorouracil/5-FU drug metabolism), tandem repeat variant                                                                 | January 1, 2017           | July 1, 2017   | CPT® 2018    |
| ▲81403 | Molecular pathology procedure, Level 4 (eg, analysis of single exon by DNA sequence analysis, analysis of >10 amplicons using multiplex PCR in 2 or more independent reactions, mutation scanning or duplication/deletion variants of 2-5 exons)  
IDH1 (isocitrate dehydrogenase 1 [NADP+], soluble) (eg, glioma), common exon 4 variants (eg, R132H, R132C)  
IDH2 (isocitrate dehydrogenase 2 [NADP+], mitochondrial) (eg, glioma), common exon 4 variants (eg, R140W, R172M)                                                                                                       | January 1, 2017           | July 1, 2017   | CPT® 2018    |
| ▲81404 | Molecular pathology procedure, Level 5 (eg, analysis of 2-5 exons by DNA sequence analysis, mutation scanning or duplication/deletion variants of 6-10 exons, or characterization of a dynamic mutation disorder/triplet repeat by Southern blot analysis)  
HBA1/HBA2 (alpha globin 1 and alpha globin 2) (eg, alpha thalassemia), duplication/deletion analysis                                                                                                           | January 1, 2017           | July 1, 2017   | CPT® 2018    |
<table>
<thead>
<tr>
<th>Code</th>
<th>Long Code Descriptor</th>
<th>Published to AMA Website</th>
<th>Effective Date</th>
<th>Publication</th>
</tr>
</thead>
</table>
| ▲81405 | Molecular pathology procedure, Level 6 (eg, analysis of 6-10 exons by DNA sequence analysis, mutation scanning or duplication/deletion variants of 11-25 exons, regionally targeted cytogenomic array analysis)  
  *CPOX (coproporphyrinogen oxidase)* (eg, hereditary coproporphyrina), full gene sequence  
  *CTRC (chymotrypsin C)* (eg, hereditary pancreatitis), full gene sequence  
  *F9 (coagulation factor IX)* (eg, hemophilia B), full gene sequence  
  *PKLR (pyruvate kinase, liver and RBC)* (eg, pyruvate kinase deficiency), full gene sequence | January 1, 2017          | July 1, 2017     | CPT® 2018        |
| ▲81406 | Molecular pathology procedure, Level 7 (eg, analysis of 11-25 exons by DNA sequence analysis, mutation scanning or duplication/deletion variants of 26-50 exons, cytogenomic array analysis for neoplasia)  
  *HMBS (hydroxymethylbilane synthase)* (eg, acute intermittent porphyria), full gene sequence  
  *PPOX (protoporphyrinogen oxidase)* (eg, variegate porphyria), full gene sequence | January 1, 2017          | July 1, 2017     | CPT® 2018        |
| ▲81406 | Molecular pathology procedure, Level 7 (eg, analysis of 11-25 exons by DNA sequence analysis, mutation scanning or duplication/deletion variants of 26-50 exons, cytogenomic array analysis for neoplasia)  
  *ANOS1 KAL1 (anosmin-1 Kallmann syndrome 1 sequence)* (eg, Kallmann syndrome 1), full gene sequence | March 1, 2017            | July 1, 2017     | CPT® 2018        |